ADMA Biologics, Inc. vs Protagonist Therapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: ADMA Biologics vs. Protagonist Therapeutics

In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, ADMA Biologics, Inc. and Protagonist Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, ADMA Biologics experienced a staggering 1,124% increase in SG&A expenses, reflecting its aggressive growth strategy. In contrast, Protagonist Therapeutics saw an 80% rise, indicating a more conservative approach.

Key Insights

• ADMA Biologics: Starting at $4.8 million in 2014, their SG&A expenses surged to nearly $59 million by 2023, highlighting significant investment in operational expansion.
• Protagonist Therapeutics: With a modest beginning of $1.86 million in 2014, their expenses grew to $33 million in 2023, suggesting steady growth.

These trends underscore the differing strategic priorities of these biotech firms, offering valuable insights for investors and industry analysts.